medline.ch Onkologie Urologische Tumoren

	[(177)Lu]Lu-PSMA-617 Plus Short-Course Priming With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Single-Arm Phase 2 Trial (Lu-PRIME). Prostate Aggarwal P, Sood A, Satapathy S, Goyal S, Kaur K, Prakash G, Periasamy K, Mittal BR. PMID: 42732593 [PubMed - as supplied by publisher]
	Side-specific lower detrusor apron-sparing robot-assisted radical prostatectomy: functional and oncological outcomes. World J Urol Buhas BA, Touzani A, Neuenschwander A, Lesourd M, Pradère B, Tollon C, Martini A, Ploussard G. PMID: 42732481 [PubMed - indexed for MEDLINE]
	Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank. Urol Oncol Msaouel P, La Rosa S, Abel EJ, Albiges L, Barata PC, Berg SA, Braun DA, Brugarolas J, Campbell MT, Carlo MI, Coleman K, Cost NG, Das A, Desai A, Dizman N, Drago D, Economides M, Geynisman DM, Griffith M, Hall T, Henske EP, Jonasch E, Khanna P, Kotecha RR, Luckenbaugh A, Maranchie JK, Master V, May AM, Motzer RJ, Ornstein MC, Ortiz MV, Pal SK, Perez JR, Rini B, Shapiro DD, Shuch BM, Singer AE, Singer EA, Stadler WM, Staehler M, Tannir NM, Vaishampayan UN, Xu W, Yip W, Zacharias NM, Voss MH. PMID: 42731937 [PubMed - as supplied by publisher]
	A Spatial Perspective on Extraprostatic Extension in Prostate Cancer: Multiscale Geometric Analysis of Multiparametric MRI. Acad Radiol Xiong H, Zou F, Chen J, Ai G, Qiao X, Wu Y, Gu X, He X. PMID: 42731898 [PubMed - as supplied by publisher]
	PROspective Prostate Cancer Infrastructure: study protocol for the ProPCI 'trials within cohorts' study. BMJ Open Wissing RO, van Elst T, Sedelaar M, Smeenk RJ, van den Berg P, van Dodewaard-de Jong JM, Lont AP, Hendriks MP, Luijendijk-de Bruin D, van de Luijtgaarden ACM, Roelofs LAJ, Vis AN, Hoekstra RJ, Bloemendal HJ, van Basten JA, Mehra N. PMID: 42731831 [PubMed - indexed for MEDLINE]
	Testosterone monitoring and supplementation in patients with intermediate- or high-risk prostate cancer treated with 6-36â€¯months of androgen deprivation therapy and radiotherapy: a systematic literature review. Radiother Oncol Achard V, Zapatero A, Kishan AU, Blanchard P, Horvath LG, Jereczek-Fossa BA, Tombal B. PMID: 42731757 [PubMed - as supplied by publisher]
	Metabolic plasticity in castration-resistant prostate cancer: reprogramming mechanisms and therapeutic opportunities. Cell Signal Lou Y, Lou Z, He L, Luo J. PMID: 42731739 [PubMed - as supplied by publisher]
	Preservation of the superior fascia of the pelvic diaphragm is associated with greater continence recovery after non-nerve-sparing robot-assisted radical prostatectomy. J Robot Surg Kazashi K, Washino S, Oshima M, Kayaba T, Takeuchi S, Mito K, Saito K, Miyagawa T. PMID: 42730785 [PubMed - indexed for MEDLINE]
	Advances in understanding the tumor microenvironment of neuroendocrine prostate cancer. Front Oncol Yao N, Yang Q, Chang P, Wang Y, Li H, Wu R, Zheng J, Fu W. PMID: 42729787 [PubMed]
	Association of selected ELAC2, MSR1, RNASEL and KLK3 polymorphisms with prostate cancer susceptibility in a Hungarian cohort. Pathol Oncol Res Kovacs S, Szalai R, Barati L, Hadzsiev K. PMID: 42729212 [PubMed - indexed for MEDLINE]
	Dual-center development and external validation of machine learning models integrating PSA-derived and peripheral inflammatory markers for prostate cancer diagnosis. Transl Androl Urol Yang J, Jiang Q, Wang Y, Zhou J, Li G, Yang Z, Zhou X, Pu B, Zeng F. PMID: 42729177 [PubMed]
	Integrated bioinformatics analyses for GSDMB in carcinogenesis and progression of bladder cancer. Transl Androl Urol He J, Zhao J, Luo Y, Li M, Wang Y, Wei D. PMID: 42729139 [PubMed]
	Prognostic value of systemic immune-inflammation index in patients with localized and advanced renal cell carcinoma: a systematic review and meta-analysis. Transl Androl Urol Zhang H, Yang D, Zeng L, Wang W, Guo Z, Liao D. PMID: 42729084 [PubMed]
	Multi-omics integration identifies HSPA4 as a therapeutic target and reveals DON-induced endoplasmic reticulum stress in bladder cancer. Transl Androl Urol Zhou J, Geng J, Qiu H, Guo J. PMID: 42729077 [PubMed]
	Efficacy and safety of first-line immunotherapy in advanced renal cell carcinoma: a systematic review and network meta-analysis. Transl Androl Urol Chen G, Jin Y, Su T. PMID: 42729075 [PubMed]
	Systematic characterization of neurotransmitter receptor dysregulation identifies a neural-related prognostic signature associated with biochemical recurrence in prostate cancer. Transl Androl Urol Luo S, Chen J, Dong Q, Lin W, Liu L, He X, Zhang Y. PMID: 42729070 [PubMed]
	Sexual function outcomes following prostate cancer treatment in sexual and gender minority populations: a mixed-methods systematic review. Transl Androl Urol Burr KA, Chen CH, Kharwadkar S, Liu WME, Cotton A, Yap T. PMID: 42729069 [PubMed]
	CCNA2 orchestrates the PI3K/AKT signaling axis to propel prostate cancer metastasis. Transl Androl Urol Sun J, Zhao Q, Kong L, Wang Y, He J, Ren M. PMID: 42729059 [PubMed]
	Initial experience and technical description of robot-assisted single-port laparoscopic bilateral inguinal lymph node dissection for penile cancer: a report of two cases. Transl Androl Urol Yang C, Sun Q, Zhou R, Zhu Z, Wu B, Xia H, Xia M, Liu C. PMID: 42729024 [PubMed]
	An interpretable biparametric MRI habitat radiomics model for predicting bone metastasis in prostate cancer: a dual-center study. Transl Androl Urol Gong J, Li F, Sun Y, Huang J, Zhang Y, Yang O, Li J, Song Z, Ai K, Huang G. PMID: 42729016 [PubMed]

Artikel 1 - 20 / 181405

Seite 1 von 9071

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung